Abstract:Primary immune thrombocytopenia (ITP) is an acquired autoimmune inflammatory bleeding disorder with elevated expression of tumor necrosis factor-α (TNF-α) (Pehlivan M et. al. Platelets 2011). In our current study, we isolated the CD14+ monocytes from ITP patients and healthy controls, and performed qPCR assay to test the expression of TNF-α. In ITP patients positive for anti-GPIIbIIIa antibody, monocytes expressed significantly higher levels of TNF-α than that in anti-GPIIbIIIa antibody negative patients or healthy controls, indicating that TNF-α may play an important role in anti-GPIIbIIIa antibody mediated Fc-dependent thrombocytopenia. Monocytes and macrophages are the major cell types involved in Fc-dependent platelet clearance in ITP. Monocytes can be divided into three groups based on their CD16 expressions, including the classical (CD14++CD16−), intermediate (CD14++CD16+) and non-classical (CD14+CD16++) monocytes. Macrophages consist of the classically activated M1 type (TNFα+, iNOS+) and the alternatively activated M2 type (CD206+). The CD16+ monocytes (intermediate and non-classical monocytes) and M1 macrophages are pro-inflammatory with increased TNF-α expression. In our current and previous studies, we discovered a deviation of the monocyte/macrophage system manifesting in an increased percentage of intermediate monocytes in the peripheral blood and elevated M1 macrophages in the spleens of ITP patients (Feng Q et. al. J Thromb Haemost 2017). We carried out in vitro blockade of TNF-α using the monoclonal TNF-α antibody in the peripheral blood mono-nuclear cells (PBMCs) of ITP patients and bone marrow-derived M1 macrophages induced by LPS and IFN-γ. We found that blockade of TNF-α could significantly decrease the percentage of CD16+ monocytes and lower the expression of M1 markers like iNOS, TNF, MCP1. We also isolated the classical monocytes from PBMCs and cultured with M-CSF to generate macrophages. Interestingly, CD16 could be expressed by the classical monocyte-derived macrophagesduring the cultivation, while intervention by TNF-α blockade could reduce the CD16 expression during the macrophage-induction process. This finding further indicates the pro-inflammatory role of TNF-a in the monocyte/macrophage system. Subsequently, we performed western blotting to investigate the mechanisms of TNF-α blockade in regulation of the balance of monocytes/macrophages using cultured bone marrow derived macrophages and found TNF-α blockade could induce autophagy in an Akt/PI3K/mTOR-dependent pathway. To determine the effect of TNF-α blockade on the function of monocytes/macrophages, we performed the phagocytosis assay using FITC-dextran. It was shown that TNF-α blockade could significantly dampen the phagocytic ability of monocyte-derived macrophages from ITP patients and M1 of RAW264.7 cell line. We also isolated the CD4+ T cells from ITP patients and labeled them with CFSE to test the function of monocyte-derived macrophages for stimulating T cell proliferation. The results showed that TNF-α blockade could significantly inhibit the stimulation of T cell proliferation by M1 macrophages. Finally, in the in vivo study, we established the murine passive ITP model by injecting anti-GPIIbIIIa antibody. We then performed flow cytometry to determine the subtypes of monocytes/macrophages after 7 days of injection. The ITP mice were treated with TNF-α antibody at 5mg/kg or isotype IgG control every other day. We observed that TNF-α blockade could ameliorate thrombocytopenia in the murine model by decreasing non-classical monocytes(ly6c-CD11b+CD115+) from peripheral blood and M1 macrophages(F4/80+TNFα+) from abdomen, liver and spleen. Additionally, we injected the DIR-labeled platelets into those ITP mice and found TNF-α blockade could reduce the rentention of platelets in spleen and liver. Our study showed that TNF-α blockade could decrease the antibody-mediated platelet destruction by restoring the monocyte/macrophage subsets in vitro and in vivo. Therefore, TNF-α blockade might be a promising therapeutic strategy for the management of ITP patients especially those positive for anti-GPIIbIIIa auto-antibody. Download : Download high-res image (200KB) Download : Download full-size image Figure . Disclosures No relevant conflicts of interest to declare.

Neutrophil Extracellular Traps (NETs) Contribute to the Formation of Microvascular Thrombosis in Immune Thrombotic Thrombocytopenic Purpura

Targeting Neutrophil Extracellular Trap Accumulation under Flow in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Aberrant Expression of NLRP3, NLRC4 and NLRP6 Inflammasomes in Patients with Primary Immune Thrombocytopenia

Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?

Plasma levels of S100A8/A9, histone/DNA complexes, and cell‐free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura

Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia

Neutrophil Extracellular Traps Induce Intestinal Damage and Thrombotic Tendency in Inflammatory Bowel Disease

Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis

Neutrophil extracellular traps contribute to tissue plasminogen activator resistance in acute ischemic stroke

Plasma Levels of Histone-DNA Complex and Cell-Free DNA Predict Mortality in Patients with Immune Thrombotic Thrombocytopenic Purpura

Abstract 569: Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and -Independent Mechanisms

Neutrophil Extracellular Traps and Thrombolysis Resistance: New Insights for Targeting Therapies

ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura

ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow

Tnf-Alpha Blockade Inhibits Pro-Inflammatory Monocytes/Macrophages In Itp

Neutrophil extracellular traps mediated by platelet microvesicles promote thrombosis and brain injury in acute ischemic stroke

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

IRGM/Irgm1 deficiency inhibits neutrophil-platelet interactions and thrombosis in experimental atherosclerosis and arterial injury

Neutrophil Extracellular Traps in Ischemic Stroke Thrombi Are Associated Wth Poor Clinical Outcome

Neutrophil extracellular traps promote thrombogenicity in cerebral venous sinus thrombosis

Neutrophil Extracellular Traps Activated by Damage Associated Molecular Patterns Exacerbates Sterile Inflammatory Liver Injury (INM1P.427)